Pascal Biosciences has three programs in preclinical development for oncology indications. We have demonstrated in animal glioblastoma models that our lead product – PAS-403 – synergizes with temozolomide and radiation to extend life expectancy. GMP manufacturing for PAS-403 will occur in 2019 and we expect to submit an IND application for Glioblastoma and brain metastases in early 2020. Our second program – PAS-393 – is a small molecule targeting increased immune surveillance. When used in combination with checkpoint inhibitors we think this will increase the percentage of patients benefiting from this important therapy. We also have antibodies in development that target the pre-B cell receptor found only in pro-B and pre-B cells. We think this will have utility in lymphomas and acute lymphoblastic leukemia while preserving the B-cell portion of the immune system in order to combat infection. We are seeking partners for each of these programs.